Drug Clinical Trials List

Display 531 - 540 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Grazoprevir/Elbasvir For Treatment Of Hepatitis C Virus Genotype 4 Post Kidney Transplant	King Faisal Specialist Hospital & Research Center (MSD grant)	Ongoing	Zepatier	4	2171009	King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition.	SPIMACO ADDWAEIH	Ongoing	solifenacin succinate	BE	Feb-17	Saudi Ajal
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation	Novartis	Ongoing	Ruxolitinib (INC424) (Jakavi)	3	CINC424D2301	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients.	King Abdullah Medical City, Makkah	Ongoing	Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL	2	IRB#17-329 version2	King Abdullah Medical City (Makkah)
<p style="text-align: justify;">Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of<br />Transfusional Iron Overload in Patients with Sickle Cell Disease<br />or Other Anemias</p>	ApoPharma	Ongoing	Deferiprone	3b	LA38-EXT	Aseer Central Hospital
Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial	King Abdullah Medical City, Makkah	Ongoing	VITAMIN D3 (CHOLECALCIFEROL)	3	IRB#16-252, V2	King Abdullah Medical City (Makkah)
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation	Novartis	Ongoing	Ruxolitinib (INC424) (Jakavi)	3	CINC424C2301	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma	Archigen Biotech Limited	Ongoing	Rituximab/ SAIT101	3	AGB 002	Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam)
"A PHASE 2/3, MULTICENTER, MULTINATIONAL,OPEN-LABEL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUMCOFACTOR DEFICIENCY (MOCD) TYPE A"	Alexion	Ongoing	ALXN1101( Cyclic pyranopterin monophosphate monohydrobromide dihydrate)	2b	ALXN1101-MCD-202	King Fahad Medical City (Riyadh)
A Phase 4, Double-Blind, Randomised, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa	AbbVie	Ongoing	Adalimumab	4	M15-574	King Faisal Specialist Hospital and Research Center (Riyadh)